Cartesian Therapeutics (NASDAQ:RNAC) Posts Earnings Results, Beats Estimates By $1.34 EPS

Posted by on Aug 8th, 2026

Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report) issued its earnings results on Thursday. The company reported $0.46 EPS for the quarter, beating the consensus estimate of ($0.88) by $1.34, Zacks reports.

Cartesian Therapeutics Stock Performance

NASDAQ:RNAC traded up $0.09 on Friday, hitting $8.85. The stock had a trading volume of 83,713 shares, compared to its average volume of 140,879. Cartesian Therapeutics has a 1 year low of $5.60 and a 1 year high of $12.25. The firm’s fifty day simple moving average is $8.58 and its two-hundred day simple moving average is $7.55. The stock has a market cap of $260.01 million, a P/E ratio of -1.49 and a beta of 0.63.

Hedge Funds Weigh In On Cartesian Therapeutics

Several institutional investors have recently modified their holdings of RNAC. Marshall Wace LLP increased its holdings in Cartesian Therapeutics by 110.1% during the fourth quarter. Marshall Wace LLP now owns 178,140 shares of the company’s stock worth $1,284,000 after buying an additional 93,334 shares during the last quarter. Walleye Capital LLC purchased a new position in Cartesian Therapeutics in the fourth quarter valued at about $316,000. Renaissance Technologies LLC purchased a new position in Cartesian Therapeutics in the fourth quarter valued at about $296,000. Geode Capital Management LLC grew its position in shares of Cartesian Therapeutics by 5.7% during the 4th quarter. Geode Capital Management LLC now owns 255,539 shares of the company’s stock valued at $1,843,000 after acquiring an additional 13,710 shares during the period. Finally, Millennium Management LLC bought a new position in shares of Cartesian Therapeutics during the 3rd quarter valued at approximately $259,000. 86.95% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have recently weighed in on RNAC. Zacks Research raised Cartesian Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. HC Wainwright reduced their price target on shares of Cartesian Therapeutics from $30.00 to $25.00 and set a “buy” rating for the company in a research report on Tuesday, May 12th. BTIG Research restated a “buy” rating and set a $44.00 price target on shares of Cartesian Therapeutics in a research note on Tuesday, June 9th. Wedbush restated an “outperform” rating and set a $38.00 price objective on shares of Cartesian Therapeutics in a report on Wednesday, June 10th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Cartesian Therapeutics in a research note on Tuesday, June 9th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Cartesian Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $32.60.

View Our Latest Report on Cartesian Therapeutics

About Cartesian Therapeutics

(Get Free Report)

Cartesian Therapeutics, trading on NASDAQ under the symbol RNAC, is a clinical‐stage biotechnology company specializing in the development of messenger RNA (mRNA)-based therapeutics. The company leverages a proprietary RNA delivery platform to induce the production of therapeutic proteins within patients, aiming to address a range of diseases through in vivo expression of disease-modifying agents. Cartesian’s technology is designed to optimize mRNA stability, translation efficiency and targeted delivery, with potential applications spanning oncology, autoimmune disorders and rare genetic conditions.

At the core of Cartesian’s approach is a synthetic mRNA platform that incorporates proprietary lipid nanoparticle (LNP) formulations.

Featured Stories

Earnings History for Cartesian Therapeutics (NASDAQ:RNAC)

Receive News & Ratings for Cartesian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cartesian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.